↓ Skip to main content

The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, March 2018
Altmetric Badge

Mentioned by

twitter
3 X users

Citations

dimensions_citation
103 Dimensions

Readers on

mendeley
94 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance
Published in
Journal of Experimental & Clinical Cancer Research, March 2018
DOI 10.1186/s13046-018-0728-0
Pubmed ID
Authors

Meng-Shih Weng, Jer-Hwa Chang, Wen-Yueh Hung, Yi-Chieh Yang, Ming-Hsien Chien

Abstract

The epidermal growth factor receptor (EGFR) plays important roles in cell survival, growth, differentiation, and tumorigenesis. Dysregulation of the EGFR is a common mechanism in cancer progression especially in non-small cell lung cancer (NSCLC). Suppression of the EGFR-mediated signaling pathway is used in cancer treatment. Furthermore, reactive oxygen species (ROS)-induced oxidative stress from mitochondrial dysfunction or NADPH oxidase (NOX) overactivation and ectopic expression of antioxidative enzymes were also indicated to be involved in EGFR-mediated tumor progression (proliferation, differentiation, migration, and invasion) and drug resistance (EGFR tyrosine kinase inhibitor (TKI)). The products of NOX, superoxide and hydrogen peroxide, are considered to be major types of ROS. ROS are not only toxic materials to cells but also signaling regulators of tumor progression. Oxidation of both the EGFR and downstream phosphatases by ROS enhances EGFR-mediated signaling and promotes tumor progression. This review primarily focuses on the recent literature with respect to the roles of the EGFR and ROS and correlations between ROS and the EGFR in tumor progression and EGFR TKI resistance. The evidence discussed in this article can serve as a basis for basic and clinical research to understand how to modulate ROS levels to control the development and drug resistance of cancers.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 94 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 17 18%
Student > Bachelor 13 14%
Researcher 7 7%
Student > Master 7 7%
Student > Doctoral Student 5 5%
Other 18 19%
Unknown 27 29%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 24 26%
Pharmacology, Toxicology and Pharmaceutical Science 7 7%
Agricultural and Biological Sciences 7 7%
Chemistry 5 5%
Medicine and Dentistry 5 5%
Other 15 16%
Unknown 31 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 April 2020.
All research outputs
#19,951,180
of 25,382,440 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#1,462
of 2,380 outputs
Outputs of similar age
#258,440
of 351,776 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#29
of 42 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,380 research outputs from this source. They receive a mean Attention Score of 4.8. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,776 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.